abstract |
Methods of using pharmaceutical formulations with imidazo[1,2-a]-pyridin-3-yl-amide or -amine compounds as active ingredients to inhibit nitric oxide synthase are disclosed. Treatments of certain conditions using imidazo[1,2-a]-pyridin-3-yl-amide or -amine compounds are also disclosed, as are processes for preparing imidazo[1,2-a]-pyridin-3-yl-amide or -amine compounds. |